Mr. David Pidduck reports

MEDIPHARM LABS ACHIEVES PHARMACEUTICAL GMP CERTIFICATION WITH BRAZILIAN HEALTH AUTHORITY

Medipharm Labs Corp. has received good manufacturing practices certification for its Barrie, Ont., facility from Anvisa, the governing body of Brazil's pharmaceutical industry. Medipharm Labs now has GMP certification from the United States Food and Drug Administration, European Union, and Australia's Therapeutic Goods Administration, and holds a drug establishment licence from Health Canada.

Commercial opportunity

This Anvisa GMP certification inspection is the first of its kind for a purpose-built cannabis facility in North America and rare for a global GMP facility that manufactures botanical cannabidiol and tetrahydrocannabinol. The Anvisa GMP certification further solidifies Medipharm's position as a global leader in the development and production of pharmaceutical cannabinoids. The Anvisa GMP means Brazilian patients can now purchase products which adhere to the strictest manufacturing processes completed in an Anvisa-accredited facility. This distinction will provide further access to the Brazilian medical cannabis market as well as facilitate access to additional global markets that recognize Medipharm's growing list of pharmaceutical certifications.

The Brazilian medical cannabis market is expected to reach $380-million in 2025, according to a 2023 report by industry observer Kaya Mind.

Medipharm Labs currently manufactures two medical cannabis products with full Anvisa product authorization under Brazil's Resolution 327/19, which governs high-value prescription cannabis products in Brazil. Additional product authorizations are currently under review with Anvisa.

In addition to existing Brazilian customers, the company entered into a supply agreement with a top-tier generic pharmaceutical company in Brazil in July, 2023. Since signing the agreement, the customer has applied to Anvisa for a number of Medipharm produced cannabis product marketing authorizations. The receipt of GMP certification is a key milestone and critical required element of the rigorous Anvisa pharma product approval process.

GMP certification details

The five-day in-person inspection, completed in December, 2023, was initiated in relation to Medipharm's current medical cannabis product authorizations through its Brazilian customer base. A product authorization was only possible based on the company's Health Canada pharmaceutical drug establishment licence, product-specific GMP validation and various long-term stability studies.

The inspection focused on Medipharm's quality management system and manufacturing capabilities for finished goods in relation to Anvisa GMP regulations, which have an international pharmaceutical industry reputation of strict compliance. Following the inspection, Medipharm was presented with observations. Medipharm responded in writing to all observations via a voluntary corrective action plan. The company's Brazilian clients and Anvisa accepted these actions, resulting in a compliant GMP status.

Management commentary

"This GMP certification from Brazil strengthens Medipharm's position as one of the most pharmaceutically focused medical cannabis companies in the world. The certification joins our long list of global regulatory achievements, including U.S. FDA, Australian TGA, European Union pharmaceutical GMP and Canadian pharmaceutical GMP authorizations. Whether it is the production for cannabis-based drug research, international cannabis medical programs or future marketable cannabis drugs, Medipharm has invested in and executed on the development of global pharmaceutical and medical channels. We believe this positions us well for future growth with a suite of capabilities, certifications and approvals unmatched globally," commented David Pidduck, Medipharm Labs chief executive officer.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a good manufacturing practices certified facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic good manufacturing practices licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the company's current foreign drug manufacturing site registration with the U.S. FDA.

In 2023, Medipharm acquired VIVO Cannabis Inc. which expanded Medipharm's reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Pty. and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada which provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

We seek Safe Harbor.